

NCCN Clinical Practice Guidelines in Oncology™

Soft Tissue Sarcoma

V.2.2008

Continue

www.nccn.org

NCCN Soft Tissue Sarcoma Panel Members

***George D. Demetri, MD/Chair †**
Dana-Farber/Brigham and Women's Cancer
Center | Massachusetts General Hospital
Cancer Center

Laurence H. Baker, DO †
University of Michigan Comprehensive
Cancer Center

Robert S. Benjamin, MD †
The University of Texas M. D. Anderson
Cancer Center

Ephraim S. Casper, MD † ‡
Memorial Sloan-Kettering Cancer Center

Ernest U. Conrad, III, MD ¶ τ
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

Gina Z. D'Amato, MD ‡ †
H. Lee Moffitt Cancer Center & Research
Institute

Thomas F. DeLaney, MD §
Dana-Farber/Brigham and Women's Cancer
Center | Massachusetts General Hospital
Cancer Center

David S. Ettinger, MD †
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins

Robert Heck, Jr., MD ¶
University of Tennessee Cancer Institute

Martin J. Heslin, MD ¶
University of Alabama at Birmingham
Comprehensive Cancer Center

Raymond J. Hutchinson, MD € ξ
University of Michigan Comprehensive
Cancer Center

Charlotte D. Jacobs, MD †
Stanford Comprehensive Cancer Center

John M. Kane III, MD ¶
Roswell Park Cancer Institute

Krystyna Kiel, MD §
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

G. Douglas Letson, MD ¶
H. Lee Moffitt Cancer Center & Research
Institute

Sean V. McGarry, MD
UNMC Eppley Cancer Center at The
Nebraska Medical Center

Richard J. O'Donnell, MD ¶
UCSF Helen Diller Family Comprehensive
Cancer Center

I. Benjamin Paz, MD ¶
City of Hope

John D. Pfeifer, MD ≠
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University School
of Medicine

Raphael E. Pollock, MD ¶
The University of Texas M. D. Anderson
Cancer Center

R. Lor Randall, MD ¶
Huntsman Cancer Institute at the University
of Utah

Karen D. Schupak, MD §
Memorial Sloan-Kettering Cancer Center

Herbert S. Schwartz, MD ¶
Vanderbilt-Ingram Cancer Center

Douglas S. Tyler, MD ¶
Duke Comprehensive Cancer Center

***Margaret von Mehren, MD †**
Fox Chase Cancer Center

Jeffrey Wayne, MD ¶
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

† Medical Oncology
¶ Surgery/Surgical oncology
‡ Internal medicine
τ Orthopedics/orthopedic oncology
§ Radiotherapy/Radiation oncology
€ Pediatric oncology
ξ Bone Marrow Transplantation
≠ Pathology
*Writing Committee Member

Continue

Table of Contents

[NCCN Soft Tissue Sarcoma Panel Members](#)

[Summary of Guidelines Updates](#)

Soft Tissue Sarcoma

- [Soft-Tissue Extremity \(EXTSARC-1\)](#)
- [Retroperitoneal/Abdominal \(RETSARC-1\)](#)
- [Intra-abdominal Sarcomas \(ABSARC-1\)](#)
 - ▶ [Gastrointestinal Stromal Tumors \(GIST-1\)](#)
 - ▶ [Principles of Biopsy \(GIST-A\)](#)
 - ▶ [Other Intra-abdominal Sarcomas \(GISARC-1\)](#)

- [Desmoid Tumors \(DESMSARC-1\)](#)

[Principles of Surgery \(SARC-A\)](#)

[Guidelines for Radiation Therapy \(SARC-B\)](#)

[Systemic Therapy Agents and Regimens \(SARC-C\)](#)

Bone Sarcomas - [See the NCCN Bone Cancer Guidelines](#)

Uterine Sarcomas - [See the NCCN Uterine Cancer Guidelines](#)

Dermatofibrosarcoma Protuberans - [See the NCCN Dermatofibrosarcoma Protuberans Guidelines](#)

[Guidelines Index](#)

[Print the Sarcoma Guideline](#)

[For help using these documents, please click here](#)

[Staging](#)

[Manuscript](#)

[References](#)

Clinical Trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, [click here:
nccn.org/clinical_trials/physician.html](#)

NCCN Categories of Evidence and Consensus: All recommendations are Category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#)

The NCCN Soft Tissue Sarcoma Guidelines do not include the management of Rhabdomyosarcoma, Ewing's Sarcoma, or Desmoplastic small round cell tumors.

These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2008.

Summary of the Guidelines updates

Summary of the changes in the 2.2008 version of the Soft Tissue Sarcoma Guidelines from the 1.2008 version include the addition of the manuscript to reflect the changes in the algorithm ([MS-1](#)).

Summary of changes in the 1.2008 version of the Soft Tissue Sarcoma Guidelines from the 3.2007 version include:

Extremity

[EXTSARC-1](#)

- Footnote b is new to the page stating that CT angiograms may be useful for patients in whom an MRI is not feasible.
- The recommendation was added to "Consider MRI of total spine for round cell liposarcoma" in certain circumstances.

[EXTSARC-2](#)

- Evaluation for rehabilitation (PT/OT) was added to the Follow-up section with the additional recommendation to "continue until maximal function is achieved".

[EXTSARC-3](#)

- A category 2B designation was assigned to preoperative chemotherapy or chemoradiation for patients with resectable disease and acceptable functional outcomes.
- A category 2B designation was added to all adjuvant chemotherapy options.
- Footnote "o" is new to the page describing that there are limited data to support the use of adjuvant chemotherapy in stage II or stage III patients.
- Evaluation for rehabilitation (PT/OT) was added to the Follow-up section with the additional recommendation to "continue until maximal function is achieved".

[EXTSARC-4](#)

- This is a new page developed to address unresectable stage II, III, and IV disease at primary presentation.

Gastrointestinal Stromal Tumors (GIST)

[GIST-1](#)

- The clarification of "in selected patients" was added to Endoscopic ultrasound in the workup section.
- "Anatomic location" was added to footnote "e".

[GIST-4](#)

- Footnote "q" was clarified to define the patient population recommended for adjuvant therapy, "in patients with intermediate to high risk GIST."

Intra-abdominal sarcomas other than GIST

[GISARC-1](#)

- Chest CT was changed to "± chest imaging" in the Follow-up section.

Desmoid Tumors

[DESMSARC-1](#)

- Evaluation for rehabilitation (PT/OT) was added to the Follow-up section with the additional recommendation to "continue until maximal function is achieved".

Principles of Surgery

[SARC-A](#)

- The additional recommendation to "continue until maximal function is achieved" was added to the last bullet.

WORKUP


ESSENTIAL:

- All patients should be managed by a multidisciplinary team with expertise in sarcoma
- H&P
- Adequate imaging^a of primary tumor is indicated for all lesions with a reasonable chance of being malignant (MRI ± CT)^b
 - Plain radiograph of primary tumor (optional)
- Carefully planned biopsy (core needle or incisional biopsy after adequate imaging, placed along longitudinal axis, with minimal dissection and careful attention to hemostasis)^c
 - Biopsy should establish grade and histologic subtype
 - Appropriate use of expert molecular and cytogenetic analysis^d

• Chest imaging

USEFUL UNDER CERTAIN CIRCUMSTANCES:

- PET scan may be useful in prognostication, grading and determining response to chemotherapy
- Consider abdominal/pelvic CT for myxoid liposarcoma, epithelioid sarcoma, angiosarcoma, and leiomyosarcoma
- Consider MRI of total spine for round cell liposarcoma



^aAdequate imaging should provide details about the size of tumor and contiguity to nearby visceral structures and neurovascular landmarks.

^bCT angiogram may be useful for patients in whom an MRI is not feasible.

^cIn selected institutions with clinical and pathologic expertise, an FNA may be acceptable.


^dMolecular diagnostic techniques can be useful in establishing the diagnosis of synovial sarcoma, clear cell sarcoma, and liposarcoma.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRIMARY THERAPY

FOLLOW-UP



^eSee the American Joint Committee on Cancer (AJCC) Staging Manual, 6th Edition for conversion to a three or four tiered grading system.

^f[See Principles of Surgery \(SARC-A\).](#)

^gReresection, if feasible, may be necessary to render margins > 1.0 cm.

^hRandomized clinical trial data support the use of radiotherapy (category 1) as an adjunct to surgery in appropriately selected patients based on an improvement in disease-free survival (although not overall survival). The preferred timing of treatment (preoperative vs postoperative) has not been defined.


ⁱ[See Guidelines for Radiation Therapy \(SARC-B\).](#)

^jIn situations where the area is easily followed by physical examination, imaging may not be required.

^kAfter 10 y, the likelihood of developing a recurrence is small and follow-up should be individualized.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^jIn situations where the area is easily followed by physical examination, imaging may not be required.

^kAfter 10 y, the likelihood of developing a recurrence is small and follow-up should be individualized.

^lTreatment options for stage II and III should be made by a multimodality team and involve consideration of the following: performance status, comorbid factors (including age), site of disease, histologic subtype, institutional experience.


^m[See Principles of Systemic Therapy \(SARC-C\).](#)

ⁿSurgery may be an option for small tumors resected with wide margins.

^oThere are limited data to support the use of adjuvant chemotherapy in stage II or stage III patients.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^jIn situations where the area is easily followed by physical examination, imaging may not be required.

^kAfter 10 y, the likelihood of developing a recurrence is small and follow-up should be individualized.

^lTreatment options for stage II and III should be made by a multimodality team and involve consideration of the following: performance status, comorbid factors (including age), site of disease, histologic subtype, institutional experience.

^m[See Principles of Systemic Therapy \(SARC-C\).](#)

^oThere are limited data for adjuvant chemotherapy in stage II patients and should only be used in specific situations.


^pThoracotomy and Video-assisted thoracic surgery (VATS) should be available and used selectively depending on the clinical presentation of metastatic disease.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

RECURRENT DISEASE

THERAPY

^mSee [Principles of Systemic Therapy \(SARC-C\)](#).^PThoracotomy and Video-assisted thoracic surgery (VATS) should be available and used selectively depending on the clinical presentation of metastatic disease.**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

WORKUP


- All patients should be managed by a multidisciplinary team with expertise in sarcoma
- H&P
- Abdominal/pelvic CT with contrast ± MRI
- Preresection biopsy not necessarily required, based on degree of suspicion of other malignancies
- Biopsy is necessary for patients receiving preoperative radiotherapy or chemotherapy (CT-guided core biopsy is preferred)
- Chest imaging
- Endoscopy as indicated

Resectable


[See Primary Treatment \(RETSARC-2\)](#)Unresectable
or metastases[See Primary Treatment \(RETSARC-3\)](#)

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

^aBiopsy required if considering preoperative therapy.^bSee [Principles of Surgery \(SARC-A\)](#).^cSee [Principles of Systemic Therapy \(SARC-C\)](#).^dSee [Guidelines for Radiation Therapy \(SARC-B\)](#).[Recurrent Disease](#)
(see [RETSARC-4](#))**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRIMARY TREATMENT

[Recurrent Disease](#)
(see RETSARC-4)^cSee Principles of Systemic Therapy (SARC-C).^dSee Guidelines for Radiation Therapy (SARC-B).^eBalance risks of treatment, likelihood of rendering patient resectable, performance status of patient, with potential clinical benefits.**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

RECURRENT DISEASE



^fConsider preoperative RT and/or chemotherapy if not previously administered.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

WORKUP OF PATIENT AT
PRIMARY PRESENTATION

INITIAL DIAGNOSTIC EVALUATION

- All patients should be managed by a multidisciplinary team with expertise in sarcoma
- H&P
- Abdominal/pelvic CT with contrast, and/or MRI
- Chest imaging
- Endoscopic ultrasound (in selected patients)
- Endoscopy as indicated (if not previously done)
- Shared decision making



^aSurgery should induce minimal surgical morbidity, otherwise consider preoperative imatinib mesylate.

^bIf surgical morbidity would not improve by reducing the size of the tumor preoperatively.

^cIf surgical morbidity would be improved by reducing the size of the tumor preoperatively.

^d[See Principles of Biopsy \(GIST-A\).](#)

^eReport should include size, anatomic location and mitotic rate, fields should be in the most mitotic area.

^fMutational analysis may have predictive value and is currently being investigated. Consider molecular analysis if available.

^gSome patients may rapidly become unresectable; close monitoring is essential.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRIMARY PRESENTATION

PRIMARY TREATMENT

FOLLOW-UP THERAPY



^hSome patients may rapidly become unresectable; close monitoring is essential.

ⁱPET is not a substitute for a CT.

^jSuggested starting dose is 400 mg/day. If molecular diagnosis available and exon 9 positive, recent data support the use of imatinib at 800 mg/day.

^kIf life threatening side effects occur with imatinib not managed by maximum supportive treatment, then consider sunitinib.

^lMedical therapy is usual course of treatment, if patient bleeding or symptomatic, may proceed to surgery.

^mCollaboration between medical oncologist and surgeon necessary to determine appropriateness of surgery, following major response or sustained stable disease.

ⁿDosing can be stopped right before surgery and restarted as soon as the patient is able to tolerate oral medications.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRIMARY PRESENTATION

PRIMARY TREATMENT

FOLLOW-UP THERAPY



ⁱPET is not a substitute for CT.

^jSuggested starting dose is 400 mg/day. If molecular diagnosis available and exon 9 positive, recent data support the use of imatinib at 800 mg/day.

^kIf life threatening side effects occur with imatinib not managed by maximum supportive treatment, then consider sunitinib.


^mCollaboration between medical oncologist and surgeon necessary to determine appropriateness of surgery, following major response or sustained stable disease.

^oMay observe low-volume asymptomatic metastases.

^pIn some patients, it may be appropriate to image prior to 3 months.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




^qAdjuvant therapy should be considered for at least 12 months in patients with intermediate to high risk GIST (DeMatteo R, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. 2007 ASCO Annual Meeting; Abstract 10079). The optimal duration has not yet been determined. Patients at higher risk for disease may justify a longer course of therapy.

^rLess surveillance may be acceptable for very small tumors (< 2 cm).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

THERAPY FOR PROGRESSIVE DISEASE



^sProgression may be determined by CT or MRI with clinical interpretation; PET scan may be used to clarify if CT or MRI are ambiguous.

^tSuggest referral to a sarcoma specialty center.

^uClinical experience recommends continuing imatinib, especially if progression is slow.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF BIOPSY

- GISTs are soft and fragile tumors and biopsy may cause tumor hemorrhage and possibly increased risk for tumor dissemination.
- Consideration of biopsy should be based upon the extent of disease and suspicion of a given histologic subtype (eg, lymphoma). Endoscopic ultrasound (EUS) biopsy is preferred over percutaneous biopsy.
- Biopsy is necessary when planning neoadjuvant therapy.
- Specialized pathology, referral to specialist centers for sarcomas with complex or unusual features.
- CD 117 immunostain if GIST in differential.
- Consider investigational mutation assay for CD 117 (KIT) negative tumors.
- GISTs should be handled with care to avoid tumor rupture. The goal is to achieve complete gross resection with an intact pseudo-capsule.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRESENTATION

PRIMARY TREATMENT

FOLLOW-UP



^a [See Principles of Surgery \(SARC-A\).](#)


^b [See Principles of Systemic Therapy \(SARC-C\).](#)

^c If response, follow the resectable pathway.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

RECURRENT DISEASE

^a[See Principles of Surgery \(SARC-A\).](#)^b[See Principles of Systemic Therapy \(SARC-C\).](#)


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

WORKUP

PRIMARY TREATMENT

- All patients should be managed by a multi-disciplinary team with expertise in sarcoma
- H&P including evaluation for Gardner's Syndrome ([See NCCN Colorectal Screening Guidelines](#))
- Chest imaging
- Appropriate imaging of primary site with CT or MRI as clinically indicated



^aMay not be necessary if complete resection planned.

^bFor desmoids, microscopic positive margins are acceptable if achieving negative margins would produce excessive morbidity.

^c[See Principles of Systemic Therapy \(SARC-C\).](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF SURGERY

- **Biopsy of Sarcoma**

Biopsy is preferred to diagnose and grade sarcomas. Biopsy should be carried out by an experienced surgeon (or radiologist) and may be accomplished by open incisional or needle technique. Endoscopic or needle biopsy may be indicated for deep, thoracic, abdominal or pelvic sarcomas.

- **Resection Margins**

Surgical margins should be documented by both the surgeon and the pathologist in evaluating a resected specimen. Margins less than 1.0 cm should be evaluated carefully for postoperative adjuvant therapy and if possible identified intraoperatively by the surgeon.

R0 resection - No residual microscopic disease

R1 resection - Microscopic residual disease

R2 resection - Gross residual disease

- **Pathology**

Pathologic assessment of biopsies and resected specimens should be carried out by an experienced sarcoma pathologist with access to cytogenetic and molecular diagnostics.

- **Amputation**

Consideration of amputation to treat extremity sarcoma should be made for patient preference or if one or more of the following tumor characteristics occur:

- Extensive soft tissue mass and/or skin involvement
- Involvement of a major artery or nerve
- Extensive bony involvement necessitating whole bone resection
- Failure of preoperative chemotherapy or radiation therapy
- Tumor recurrence after prior adjuvant radiation


- **Limb Salvage Surgery**

Limb salvage surgery is generally preferred to achieve local tumor control with minimal morbidity.

- **Evaluate postoperative rehabilitation (PT, OT) for patients with extremity sarcoma. Continue rehabilitation until maximal function is achieved**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

GUIDELINES FOR RADIATION THERAPY¹

¹ Sophisticated treatment planning with IMRT and protons can be used to improve the therapeutic effect. If an R1 or R2 resection is anticipated, clips to high risk areas for recurrence is encouraged.

² See [Principles of Surgery \(SARC-A\)](#).

³ RT does not substitute for suboptimal surgical resection, re-resection may be necessary.

⁴ Total doses should always be determined by normal tissue tolerance.

⁵ For intra-abdominal or retroperitoneal tumors, external beam RT may be decreased to 45 Gy. A boost may not be possible if potential radiation morbidity is high.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

GENERALLY ACCEPTED SYSTEMIC THERAPY AGENTS AND REGIMENS^{a,b}Extremity, Retroperitoneal, Intra-abdominal other than GISTCombination regimens

- AD (doxorubicin, dacarbazine)^{1,2}
- AIM (doxorubicin, ifosfamide, mesna)^{3,4}
- MAID (mesna, doxorubicin, ifosfamide, dacarbazine)⁵
- Ifosfamide, epirubicin, mesna⁶
- Gemcitabine and docetaxel^{7,8}

Single agents

- Doxorubicin⁹
- Ifosfamide^{6,10}
- Epirubicin
- Gemcitabine
- Dacarbazine
- Liposomal doxorubicin¹¹

Angiosarcoma

- Paclitaxel
- Docetaxel
- Vinorelbine

Desmoid Tumors

- Sulindac¹² or other non-steroidal anti-inflammatory drugs (NSAIDs) including celecoxib^c
- Tamoxifen¹³
- Toremifene¹⁴
- Methotrexate and vinblastine¹⁵
- Low-dose interferon¹⁶
- Doxorubicin-based regimens^{17,18}
- Imatinib mesylate¹⁹

GIST

- Imatinib mesylate^{20,21}
- Sunitinib malate²²

^aAlveolar soft part sarcoma and clear cell sarcomas are generally not sensitive to chemotherapy.

^bReferences for regimens, see [SARC-C 2 of 2](#).

^cThe risk of cardiovascular events may be increased in patients receiving celecoxib. Physicians prescribing celecoxib should consider this emerging information when weighing the benefits against risks for individual patients. (FDA Talk Paper T04-61, Dec 23, 2004)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

GENERALLY ACCEPTED SYSTEMIC THERAPY AGENTS AND REGIMENS

References

- ¹Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group Study. *J Natl Cancer Inst*. 1991;83(13):926-932.
- ²Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol* 1993;11(7):1276-1285.
- ³Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. *Ann Oncol*. 2004;15(11):1667-1672.
- ⁴Edmonson J, Ryan L, Blum R, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. *J Clin Oncol*. 1993;11(7):1269-1275.
- ⁵Elias A, Ryan L, Sukes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. *J Clin Oncol* 1989;7(9): 1208-1216.
- ⁶Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant Chemotherapy for Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial. *J Clin Oncol*. 2001;19(5):1238-1247.
- ⁷Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. *J Clin Oncol* 2002;20(12):2824-31.
- ⁸Leu KM, Ostruszka U, Schewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. *J Clin Oncol* 2004;22(9):1706-1712.
- ⁹Tierney JF. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. *Lancet* 1997;350:1647-1654.
- ¹⁰Antman KH et al. Dana-Farber Cancer Institute studies in advanced sarcoma. *Semin Oncol*. 1990;1(Suppl 2):7-15.
- ¹¹Judson I, Radford J, Harris M, et al. Randomized phase II trial of pegylated liposomal doxorubicin versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2001 ;37(7):870-7.
- ¹²Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. *Cancer* 2004;100:612-620.
- ¹³Chao AS, Lai CH, Hsueh S, et al. Successful treatment of recurrent pelvic desmoid tumor with tamoxifen: case report. *Hum Reprod* 2000;15:311-313.
- ¹⁴Benson JR MK, Baum M. Management of desmoid tumours including a case report of toremifene. *Ann Oncol*. 1994;5(2):173-177.
- ¹⁵Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. *Cancer*. 2001;92(5):1259-1264.
- ¹⁶Leithner A, Schnack B, Katterschafka T, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. *J Surg Oncol* 2000;73:21-25.
- ¹⁷Seiter K, Kemeny N. Successful treatment of a desmoid tumor with doxorubicin. *Cancer* 1993;71:2242-2244.
- ¹⁸Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. *Cancer* 1993;72:3244-3247.
- ¹⁹Chugh R, Maki RG, Thomas DG, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. *J Clin Oncol* (Meeting Abstracts). 2006;24(18_suppl):9515.
- ²⁰Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;347(7):472-80.
- ²¹Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. *Lancet* 2004;364(9440):1127-34.
- ²²Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial. *Lancet*. 2006;368:1329-1338.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Staging (2002 AJCC 6th Edition)**Table 1****2002 American Joint Committee On Cancer (AJCC) Staging System For Soft Tissue Sarcoma****Primary Tumor (T)**

TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
T1	Tumor 5 cm or less in greatest dimension
T1a	Superficial tumor*
T1b	Deep tumor*
T2	Tumor more than 5 cm in greatest dimension
T2a	Superficial tumor*
T2b	Deep tumor*

*Superficial tumor is located exclusively above the superficial fascia without invasion of the fascia; deep tumor is located either exclusively beneath the superficial fascia, superficial to the fascia with invasion of or through the fascia, or both superficial yet beneath the fascia. Retroperitoneal, mediastinal, and pelvic sarcomas are classified as deep tumors

Regional Lymph Nodes (N)

NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1 [†]	Regional lymph node metastasis

[†]Presence of positive nodes (N1) is considered stage IV.

Distant Metastases (M)

MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastases

Histologic Grade

GX	Grade cannot be assessed
G1	Well differentiated
G2	Moderately differentiated
G3	Poorly differentiated
G4	Poorly differentiated or undifferentiated (four-tiered systems only)

Stage Grouping

Stage I	T1a, 1b, 2a, 2b	N0	M0	G1--2	G1	Low
Stage II	T1a, 1b, 2a	N0	M0	G3--4	G2--3	High
Stage III	T2b	N0	M0	G3--4	G2--3	High
Stage IV	Any T	N1	M0	Any G	Any G	High or Low
	Any T	N0	M1	Any G	Any G	High or Low

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York. (For more information, visit www.cancerstaging.net.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer-Verlag New York, Inc., on behalf of the AJCC.

Histopathologic Type

Tumors included in the soft tissues category are listed below:

Alveolar soft-part sarcoma	Fibrosarcoma
Desmoplastic small round cell tumor	Leiomyosarcoma
Epithelioid sarcoma	Liposarcoma
Clear cell sarcoma	Malignant fibrous histiocytoma
Chondrosarcoma, extraskeletal	Malignant hemangiopericytoma
Osteosarcoma, extraskeletal	Malignant peripheral nerve sheath tumor
Gastrointestinal stromal tumor	Rhabdomyosarcoma
Ewing's sarcoma/primitive neuroectodermal tumor	Synovial sarcoma
	Sarcoma, NOS

Manuscript

NCCN Categories of Evidence and Consensus

Category 1: Based on high-level evidence and uniform consensus.

Category 2A: Based on lower-level evidence including clinical experience and uniform consensus.

Category 2B: Based on lower-level evidence including clinical experience and nonuniform consensus (but no major disagreement).

Category 3: Based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.

Overview

Sarcomas constitute a heterogeneous group of rare solid tumors of mesenchymal cell origin with distinct clinical and pathological features; they are usually divided into two broad categories:

- Sarcomas of soft tissues (including fat, muscle, nerve and nerve sheath, blood vessels, and other connective tissues); and
- Sarcomas of bone.

Soft tissue sarcomas are the most frequent sarcomas.^{1,2} The annual incidence of soft tissue sarcomas in the United States for 2008 is estimated to be about 10,390 cases, with an overall mortality rate of approximately 3,680 cases per year, which includes adults and children.³ The 5-year survival rate of soft tissue sarcomas is 50-60%.⁴ The true incidence of sarcomas is underestimated, especially because a large proportion of patients with the sarcoma known as gastrointestinal stromal tumor (GIST) may not have been counted in tumor registry databases before 2001. GIST is expected to have an incidence of at least 5000 new cases per year in the United States.^{5,6}

Collectively, sarcomas account for approximately 1% of all adult malignancies and 15% of pediatric malignancies; adult soft tissue sarcomas are discussed in this guideline. External radiation therapy (RT) is a risk factor for soft tissue sarcoma.⁷ Most commonly, a soft tissue sarcoma presents as an asymptomatic mass. The differential diagnosis of a soft tissue mass includes malignant lesions (such as primary or metastatic carcinoma, melanoma, or lymphoma), desmoids, and benign lesions (such as lipomas, lymphangiomas, leiomyomas, and neuromas). The size at presentation depends on the location: tumors in the proximal extremities and retroperitoneum are often quite large, whereas distal extremity tumors are often small. The anatomic site of the primary disease represents an important variable that influences treatment and outcome. Soft tissue sarcomas of the extremities account for about 50% of all sarcomas, gastrointestinal (GI) sarcomas for 25%, retroperitoneal sarcomas for 15-20%, and head and neck for 9%. The most common subtypes of soft tissue sarcomas are malignant fibrous histiocytoma, liposarcoma, leiomyosarcoma, unclassified sarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors.⁸ However, more than 50 different histologic subtypes of soft tissue sarcoma have been identified.¹ Soft tissue sarcomas most commonly metastasize to the lungs; tumors arising in the abdominal cavity more commonly metastasize to the liver and peritoneum.

The NCCN encompasses institutions with extensive experience in the management of sarcomas using primary multidisciplinary oncology care and functioning as referral centers for consultative support of community-based practitioners. The expertise of the NCCN institutions allows this group to use their extensive experience in defining these consensus practice guidelines for the management of patients with sarcomas. NCCN Soft Tissue Sarcoma guidelines do not include the management of Rhabdomyosarcoma, Ewing's sarcoma, and Desmoplastic Small Round Cell Tumor (DSCRT). These guidelines

address sarcoma management from the perspective of four disease subtypes:

- Soft tissue sarcomas of extremity
- Retroperitoneal or abdominal sarcomas
- GIST and other intra-abdominal sarcomas
- Desmoid tumors

Current staging groups and nomenclature for classifying soft tissue sarcomas are given in [Table 1](#). The American Joint Committee on Cancer (AJCC) revised this staging system in 2002, and these guidelines reflect the new staging.⁹

Principles of Surgery

Because surgery is the standard primary treatment for most sarcomas, the panel has included a separate section on principles of sarcoma surgery ([SARC-A](#)). If a patient cannot be surgically treated in accordance with these principles of sarcoma surgery, preoperative RT or chemotherapy should be considered as alternate treatment options. Because the risk of failure in the surgical bed can be high, many clinicians choose to augment surgery with RT and chemotherapy, either preoperatively or postoperatively.^{10,11,12} When appropriate, these guidelines incorporate these therapies that are supported by clinical trial data or extensive clinical experience.^{13,14}

Biopsy

Biopsy is preferred for the diagnosis and grading of sarcomas, and should be performed by an experienced surgeon or radiologist. Biopsy can be accomplished by core needle or open incisional techniques. Endoscopic or needle biopsy may be indicated for deep thoracic, abdominal or pelvic sarcomas.

Resection margins

Both the surgeon and the pathologist should document surgical margins, in evaluating a resected specimen. Margins less than 1 cm should be evaluated carefully for postoperative therapy and if possible identified intraoperatively. Re-resection, if feasible may be required to achieve optimal margins (greater than 1 cm), primarily for non-intra abdominal tumors.

Limb sparing surgery is generally preferred to achieve local tumor control with minimal morbidity.¹⁵ Evaluation for postoperative rehabilitation is recommended for all patients with extremity sarcoma. If recommended, rehabilitation should be continued until maximum function is achieved.

Amputation for Extremity Sarcoma

Amputation should be considered for patient preference or if the tumor has the following characteristics: extensive soft tissue mass and/or skin involvement, major arterial or nerve involvement, extensive bony involvement that requires whole bone resection, failure of preoperative therapy or recurrence following prior adjuvant radiation.^{16,17}

Pathology

Pathologists with sarcoma expertise should review pathology assessment of biopsies and resected specimens, especially for initial histopathologic classification. Margins must be thoroughly evaluated in these specimens. Because identification of the histopathologic type of a sarcoma is often difficult, pathologists should have access to optimal cytogenetic and molecular diagnostic techniques. Molecular and cytogenetic analysis can be useful for establishing the diagnosis of synovial sarcoma, clear cell sarcoma and liposarcoma.

Guidelines for Radiation Therapy

Sophisticated treatments with intensity-modulated radiation therapy (IMRT) and proton-beam should be considered to improve therapeutic effect.¹⁸ If resections with microscopically positive or grossly positive margins are anticipated, surgical clips should be left in place to identify high-risk areas for recurrence, particularly for retroperitoneal or intra-abdominal sarcomas ([SARC-B](#)). Total doses of RT should be determined by normal tissue tolerance.

Preoperative RT

The usual dose of preoperative RT is 50 Gy. An intraoperative boost or a postoperative boost with brachytherapy or an external-beam RT is recommended for positive or close margins.¹⁹ Preoperative RT has several advantages. First, the treatment volume is smaller, because the need to cover the operative field is not present. Second, preoperative radiation may reduce seeding during surgical manipulation of the tumor. The tumor may or may not regress with preoperative RT, but the pseudocapsule may thicken and become acellular, easing resection and decreasing the risk of recurrence. However, the main disadvantage of preoperative RT is its effect on wound healing.²⁰ A higher complication rate has been observed when primary closure is used. Therefore, involvement of a plastic surgeon in the team may be necessary to reduce wound complications when preoperative radiation is contemplated. After preoperative radiation, 3-6 weeks interval is necessary before resection to decrease the risk of wound complications. Very long intervals between resection and postoperative radiation are not recommended.

If wide margins are obtained, additional radiation may not be needed. Often, margins are close because of the proximity of many of these tumors to major neurovascular bundles or bone. At the time of resection, surgical clips should outline the area of recurrence risk. Brachytherapy boosts should be delivered several days after surgery,

through catheters placed at operation, with doses of 12-20 Gy based on margin status. Alternatively, a single intraoperative dose to the tumor bed of 10-16 Gy, based on margin status, can be delivered immediately after resection with exposure of the area at risk, avoiding uninvolved organs. External-beam RT boosts may be an alternative to brachytherapy or intraoperative radiation: recommended doses are 10-14 Gy for close margins, 16-20 Gy for microscopically positive margins, and 20-26 Gy for grossly positive margins. Many institutions are no longer giving a boost after preoperative radiation to patients who have widely negative margins, based on local control rates that approach 95% with preoperative radiation at 50 Gy and negative margins.¹⁹

Postoperative RT

Postoperative RT has been to improve local control in patients with high-grade extremity soft tissue sarcomas with positive surgical margins.²¹ When surgical resection is the initial therapy, postoperative RT choices include intraoperative radiation therapy (IORT), external beam RT or brachytherapy. RT is not a substitute for suboptimal surgical resection, and re-resection may be necessary. If the patient has not previously received RT, one could attempt to control microscopic residual disease with postoperative RT if re-resection is not feasible.

External-beam RT is delivered to large fields after surgical healing is complete (3-8 weeks) to doses of 50 Gy. Most institutions include the entire operative bed within that radiation field. Total doses of RT should always be determined by normal tissue tolerance. For intraabdominal or retroperitoneal tumors, this dose may be decreased to 45 Gy. An intraoperative boost may not be possible if radiation morbidity is high.

If no IORT or brachytherapy was used in the immediate operative or postoperative period, an external-beam RT boost should be added. For

negative margins, an additional 10-16 Gy is recommended to a reduced field that includes the original tumor bed, based on grade and width of margins. For microscopically positive margins, an additional 16-20 Gy is recommended; for grossly positive margins, an additional 20-26 Gy is suggested.

Brachytherapy alone has been used as an adjuvant in patients with negative margins. 45-50 Gy to the tumor bed has been shown to reduce recurrence without a significant effect on wound healing.²² However, brachytherapy-alone techniques require special expertise and significant experience. If brachytherapy is used as a boost, doses of 10-20 Gy based on margin are recommended; a boost dose of 10-16 Gy for close margins or 20 Gy for positive margins is recommended.

Recent reports from a retrospective study suggest that IORT provides excellent local control to soft tissue sarcoma of the extremity, when used as a boost to external beam RT.²³ However, since IORT has not been proven superior, the guidelines recommend IORT followed by a dose of 50 Gy external beam RT.

Soft Tissue Sarcomas of the Extremities

Evaluation and Workup

All patients should be managed by a multidisciplinary team with expertise in soft-tissue sarcoma.²⁴ The differential diagnosis of soft tissue sarcomas of the extremities includes ruling out desmoids, as well as the other malignant and benign lesions previously discussed. An essential element of the workup is a history and physical examination (H&P). Laboratory tests have a limited role. Adequate and high-quality imaging studies are crucial to good clinical management of patients, because the presence of metastatic disease may change the management of the primary lesion and the overall approach to the patient's disease management. Imaging studies should also provide details about tumor size and contiguity to nearby visceral structures and

neurovascular landmarks. Magnetic resonance imaging (MRI) with or without computed tomography (CT) is indicated for all lesions with a reasonable chance of being malignant ([EXTSARC-1](#)). MRI is preferred for extremity sarcomas, whereas CT is preferred for retroperitoneal sarcomas.²⁵⁻²⁷ CT angiogram may be useful for patients in whom MRI is not feasible. Plain radiograph of the primary lesion is optional. Given the risk for hematogenous spread from a high-grade sarcoma to the lungs, imaging of the chest is essential for accurate staging. Abdominal/pelvic CT should be considered for myxoid liposarcoma, leiomyosarcoma, epithelioid sarcoma or angiosarcoma and MRI of the total spine should be considered for myxoid round cell liposarcomas due the higher risk of metastasis to spine compared other soft tissue sarcomas.^{28,29,30}

Positron emission tomography (PET) scan may be useful for prognostication, grading and to assess response to chemotherapy.³¹ Tumor metabolism data acquired by PET will be useful in accurate grading and prognostication in sarcoma.³² Recent reports in literature have demonstrated the value of PET scan in evaluating response to preoperative chemotherapy in patients with high-grade extremity soft tissue sarcomas, prediction of outcome in liposarcoma.^{33,34,35} A large prospective study is underway to study the value of PET scan combined with CT scan in predicting disease-free survival in patients receiving preoperative chemotherapy for soft tissue sarcoma (www.cancer.gov/clinicaltrials/UMN-2005LS080).

Staging

The 2002 AJCC staging system accommodates some of the three- and four-tiered systems for establishing grade.⁹ However, many clinicians prefer the two-tiered system (ie, low versus high grade); therefore, this system is also used in the algorithm ([EXTSARC-2](#)). Recommendations for translating the three- and four-tiered systems into a two-tiered system are shown in [Table 1](#).

Based on the initial workup, the patients are assigned to one of the following categories:

- Low Grade tumors (Stage I)
- High-Grade Tumors (Stage II or III)
- Unresectable disease
- Recurrent disease or primary presentation of metastatic disease

Low Grade Tumors (Stage I)

Surgery is the primary treatment for stage I low-grade tumors and is considered definitive if margins are greater than 1 cm or the fascia plane is intact.^{36,37} Retrospective studies have demonstrated a local control of 90% or more for surgery alone, as reviewed by Pisters et al.³⁸ Randomized clinical trial data support using adjunctive RT in appropriately selected patients.³⁹⁻⁴⁴ In the trial (SR2) conducted by the Canadian Sarcoma group, patients with localized primary or recurrent extremity sarcomas were randomized to receive preoperative radiation following by surgery or surgical resection followed by postoperative radiation.⁴⁵ Patients receiving either preoperative or postoperative RT have similar rates of local control and progression-free survival (PFS). However, preoperative RT was associated with a greater incidence of wound complications (35% vs. 17% for postoperative RT), especially in lower extremity tumors (43% vs. 5% for upper extremity tumors).²⁰ Late treatment related side-effects were more common in patients receiving postoperative radiation, which is believed to be related to the higher postoperative RT dose (66 Gy vs. 50 Gy for preoperative RT). Therefore, the risk of local recurrence versus the toxicity of postoperative RT should be assessed before making a decision regarding radiation.

Postoperative RT is considered at some NCCN institutions when final margins are 1 cm or less. RT may not be necessary in patients with

small lesions (5 cm or less), because these tumors are less frequently associated with local recurrence.

The panel recommends surgery alone as the primary treatment for low grade stage I tumors (T1a-2b, N0, M0). Postoperative RT is included with a category 2B recommendation for T1a-1b tumors and category 1 recommendation for T2a-2b tumors ([EXTSARC-2](#)).

High-Grade Tumors (Stage II or III)

Large high-grade extremity sarcomas (greater than 10 cm) at high risk for local recurrences and metastases and should be considered for preoperative therapy. Preoperative chemotherapy or chemoradiation is used in many centers for high-grade tumors to downstage a large tumor to enable effective surgical resection, especially in the case of chemosensitive histologies.⁴⁶⁻⁵¹ Concurrent chemoradiation with doxorubicin-based regimens has been shown to improve local control rates in patients with soft tissue sarcoma.⁵² Available evidence although underpowered, suggests that anthracycline-based postoperative chemotherapy would improve disease-free survival in selected patients who are at high risk of recurrence but otherwise are in good performance status.⁵³⁻⁵⁵

Sarcoma Meta Analysis Corporation performed a meta-analysis of 14 randomized trials (1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas.⁵³ The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs relapse-free survival (RFS) in adults with localized, resectable soft tissue sarcoma of the extremity and was associated with decreased recurrence rates. However, adjuvant chemotherapy does not appear to improve overall survival (OS).⁵⁶ Another recent analysis of 674 patients with stage III soft-tissue sarcoma (1984-1999) revealed that clinical benefits from doxorubicin-based chemotherapy lasted for less than a year.⁵⁷

In an Italian randomized cooperative trial, patients with high-grade or recurrent extremity sarcoma were randomized to receive postoperative chemotherapy with epirubicin and ifosfamide or observation alone. After a median follow-up of 59 months, median disease-free survival (48 months vs. 16 months) and median overall survival (75 months vs. 46 months) were significantly better in the treatment group.^{58,59}

Remarkably little data have been generated in the adjuvant setting regarding the combination of aggressively dosed ifosfamide plus doxorubicin with growth factor support. EORTC-62931 is a completed phase III randomized study to assess the efficacy of adjuvant chemotherapy after definitive surgery in patients with excised high-grade soft tissue sarcoma at any site. Patients with macroscopically resected grade II-III tumors with no metastases were randomized to observation or chemotherapy with ifosfamide and doxorubicin with lenograstim. A planned interim analysis of this study showed that there is no survival advantage for adjuvant chemotherapy with ifosfamide and doxorubicin in patients with resected high grade soft tissue sarcoma.⁶⁰ The estimated RFS was 52% in both arms. Further analysis of this study is needed to make a detailed assessment of the role of adjuvant chemotherapy in resected soft tissue sarcoma.

Treatment options for stage II or III high-grade tumors should be decided by a multidisciplinary team, based on the performance status, comorbid factors including age, location and histologic subtype of the tumor and institutional experience.

Resectable Tumors

Surgery followed by RT with or without chemotherapy or surgery alone (for small tumors that can be resected with wider surgical margins) is the primary treatment for resectable high-grade sarcomas with potentially acceptable functional outcomes ([EXTSARC-3](#)).⁶¹ The guidelines recommend various preoperative approaches including preoperative RT, chemotherapy, or chemoradiation prior to surgery,

followed by postoperative radiation with or without chemotherapy for resectable tumors with acceptable functional outcomes and for potentially resectable tumors with concerns for adverse functional outcomes. The panel has included preoperative chemotherapy or chemoradiation for resectable disease with acceptable functional outcomes with a category 2B recommendation.

Adjuvant chemotherapy alone can be considered in the case of patients who have received preoperative radiation alone ([EXTSARC-3](#)). Since limited data is available for postoperative chemotherapy for stage II or III patients, postoperative chemotherapy or chemoradiation for stage II or III tumors is included as a category 2B recommendation for all patients with resectable tumors irrespective of the functional outcomes.

Unresectable Tumors

Unresectable tumors can be treated primarily with preoperative RT, chemotherapy or chemoradiation. Tumors that become resectable following preoperative treatment can be treated with surgery followed by postoperative RT, chemotherapy or chemoradiation ([EXTSARC-4](#)).

Patients with unresectable tumors following preoperative treatment can be observed, if they are asymptomatic. For symptomatic patients most panel members would recommend moving directly to a palliative approach, defined broadly as chemotherapy, RT, palliative surgery or best supportive care.

Metastatic Disease

Single agents (doxorubicin, ifosfamide or dacarbazine) or anthracycline-based combination regimens (doxorubicin or epirubicin with ifosfamide and/or dacarbazine) have been widely used for metastatic disease.⁶²⁻⁶⁹ Liposomal anthracyclines were found to be active as first-line treatment for advanced sarcomas with better toxicity profile than doxorubicin.^{70,71} Other chemotherapeutic agents have also been tested in clinical trials.¹¹

Gemcitabine and docetaxel was found to be highly active in patients with predominantly uterine leiomyosarcomas, who had failed ifosfamide plus doxorubicin or cannot tolerate this regimen for medical reasons.⁷² In a randomized phase II study, PFS (6.2 months vs. 3.0 months respectively) and OS (17.9 months vs. 11.5 months respectively) were superior to gemcitabine and docetaxel compared to gemcitabine alone in patients with metastatic soft tissue sarcomas.⁷³ In a separate report that was published following this study, this combination was found to be active in a variety of histologic subtypes of sarcoma.⁷⁴ In a retrospective study conducted by the French Sarcoma group in 133 patients with unresectable or metastatic soft-tissue sarcoma, gemcitabine and docetaxel combination was tolerable and demonstrated better response and survival for leiomyosarcoma.⁷⁵ Another phase II trial (MSKCC-99027) is evaluating the activity of gemcitabine, docetaxel and filgrastim in patients with recurrent or persistent unresectable leiomyosarcoma or other soft tissue sarcoma that cannot be removed by surgery.

Ecteinascidin 743 (ET-743, also known as trabectedin or Yondelis®), is a marine-derived anti-tumor agent, which has shown objective responses in phase II trials of patients with progressive soft tissue sarcomas that are refractory to chemotherapy.⁷⁶⁻⁷⁸ NCT00210665 is an ongoing multicenter, open-label single-arm study, to provide access to treatment with trabectedin for patients with persistent or recurrent soft tissue sarcoma and who are not expected to benefit from currently available treatments (<http://clinicaltrials.gov/ct2/show/NCT00210665>).

Interim overall survival data are encouraging from an ongoing phase III trial (EORTC-62961) of regional hyperthermia (RHT) versus chemotherapy with EIA (etoposide, ifosfamide, adriamycin) alone for patients with locally advanced high-risk soft tissue sarcomas, especially for extremity sarcomas.⁷⁹ After a median follow-up of 24.9 months, disease-free survival (31.7 months vs. 6.2 months respectively), local

PFS (84% vs. 64% respectively for extremity sarcomas and 57% vs. 39% respectively for body wall and abdominal sarcomas) and overall response rate 28.7% vs. 12.6% respectively) were significantly superior for patients treated with EIA plus RHT compared to those treated with EIA alone.⁷⁹

Isolated limb perfusion (ILP) has been employed in Europe as a limb sparing treatment for unresectable intermediate or high-grade extremity soft tissue sarcomas.⁸⁰ In European clinical trials, melphalan in combination with tumor necrosis factor- α (TNF- α) resulted in better response rates and limb-salvage rates compared to ILP with melphalan alone.⁸¹ Recombinant TNF α -1A and melphalan has been approved in Europe for ILP in patients with locally advanced high grade soft tissue sarcoma of the extremities.

Limited Metastases

Patients with limited metastasis confined to a single organ and limited tumor bulk or regional lymph node involvement should receive primary tumor management as described for stage II or III tumors in [EXTSARC-1](#). Another option is to consider regional node dissection for nodal involvement with or without RT or metastasectomy with or without preoperative or postoperative chemotherapy with or without RT ([EXTSARC-4](#)). The guidelines do not specify rules governing metastasectomy, which remains controversial for many cancers, including sarcoma. Several variables influence the decision to use metastasectomy, including the disease-free interval from original diagnosis to detection of the metastases, the patient's performance status, and the amount of prior therapy. Thoracotomy and video-assisted thoracic surgery (VATS) should be used selectively depending on the clinical presentation of metastatic disease. In addition, patients can also receive radiofrequency ablation or embolization procedures as an alternate method for control of metastatic lesions.

Disseminated Metastases

In the guidelines, a subsequent distinction is made between asymptomatic and symptomatic patients for those who present with disseminated disease ([EXTSARC-4](#)). One reasonable management option for asymptomatic patients is to offer close observation with a “watchful waiting” strategy; this is especially true if patients have had a very long disease-free interval and have only a minimal burden of metastases (eg, sub-centimeter pulmonary nodules). Other treatment options are similar to those described for patients with unresectable disease. In addition, the guidelines have included ablation procedures (eg, radiofrequency ablation or cryotherapy), and embolization procedures as another option for symptomatic patients with disseminated metastases. The guidelines are intentionally nonspecific about this group of options, because many different issues are factored into this decision (eg, patient performance status, patient preferences, specific clinical problems from the metastases, treatment availability), and specific details are best left to clinical judgment.

Surveillance

Surveillance is deemed important to detect recurrences that might still be potentially curable. However, very limited data is available in the literature on effective surveillance strategies.⁸²⁻⁸⁴ The guidelines outline a prudent follow-up schedule that avoids excessive testing. Higher grade and larger tumors have a higher risk of dissemination; therefore, the surveillance recommendations for patients with these tumors are somewhat more intensive, particularly for the first 3 years after resection. Periodic imaging (MRI, CT, or ultrasound) of the primary site should be done based on the estimated risk of locoregional recurrence. However, in situations where the area is easily followed by physical examination, imaging may not be required. After 10 years, the likelihood of developing a recurrence is small and follow-up should be individualized.

Stage I tumors are routinely followed with H&P every 3-6 months for 2-3 years and then annually ([EXTSARC-2](#)). Baseline imaging should be considered after primary therapy. Chest x-ray should also be considered every 6 to 12 months.

For stage II and stage III tumors, H&P and chest imaging (plain radiograph or chest CT) should be done every 3-6 months for 2-3 years, then every 6 months for the next 2 years, and then annually ([EXTSARC-3](#) and [EXTSARC-4](#)). Because these patients’ risk never returns to zero, long-term follow-up is indicated, including consideration of MRI or CT scanning.⁸⁵ Chest imaging (plain radiograph or chest CT) is performed every 3-6 months for 5 years and then annually, given the risk of metastatic disease in these high-grade lesions. There has never been a study to prove that the use of more sensitive CT scans in routine surveillance would improve clinical outcomes. According to the reported data from M. D. Anderson Cancer Center, routine use of chest CT adds little clinical benefit, when risk of pulmonary metastases is low.⁸⁶ However, in certain subsets of patients in whom chest radiographs are difficult to interpret because of anatomic considerations (scarring, emphysema, etc.), chest CT surveillance may be indicated.⁸²

Recurrent Disease

The management of recurrent disease or primary presentation with metastases ([EXTSARC-5](#)) encompasses a heterogeneous group of patients and clinical scenarios. For a patient with a local recurrence, treatment decisions should be made using the same algorithm as for patients with a new primary lesion ([EXTSARC-2](#) and [EXTSARC-3](#)).⁸⁷ For patients who present with metastatic recurrences the guidelines distinguish between widely disseminated metastases and limited metastases confined to a single organ and the treatment options are similar to that described for metastatic disease at presentation ([EXTSARC-4](#)).

Retroperitoneal Abdominal Soft Tissue Sarcomas

Evaluation and Workup

The initial evaluation and workup for retroperitoneal abdominal soft tissue sarcomas are similar to that for the extremity sarcomas. This workup involves a thorough H&P and appropriate imaging studies, including an abdominal and pelvic CT with contrast with or without an MRI ([RETSARC-1](#)). Chest imaging with a plain radiograph or CT should be done, especially for patients whose tumors warrant preoperative or postoperative chemotherapy. If possible, a multidisciplinary sarcoma panel should review the patient. Note that for staging, all retroperitoneal lesions are considered deep lesions.

The differential diagnosis of retroperitoneal abdominal soft tissue mass includes malignant lesions (such as other sarcomas, GIST, lymphomas, or germ cell tumors), desmoids, and benign lesions. The need for a biopsy remains somewhat controversial, and this decision should be based on the clinician's degree of suspicion that another malignancy is possible. Proof of the histologic subtype by biopsy is necessary for patients before receiving preoperative chemotherapy or RT; a CT-guided core biopsy is preferred. The goal of this strategy is to avoid inappropriate major resection of another tumor, such as an intra-abdominal lymphoma or germ cell tumor. If a retroperitoneal sarcoma is encountered unexpectedly at the time of laparotomy performed for some other reason, a core biopsy should be done to establish the diagnosis as well as the histopathologic type and grade of tumor. Then, the optimal subsequent resection could be performed.

Primary Treatment

Surgery is the standard treatment for retroperitoneal abdominal sarcomas. Complete surgical resection or macroscopic surgical resection is only achieved in less than 70% of patients with primary retroperitoneal sarcomas, because they often are near vital structures. Local recurrence occurs in approximately half of the patients who have

undergone complete resection. Multimodality treatment is usually favored for retroperitoneal sarcomas due to the inability to obtain negative margin resections and high local recurrence rates.⁸⁸

Preoperative RT is often preferred, because the volume of abdominal organs in the RT fields is smaller and it may render unresectable tumors more amenable to resection. Preoperative chemotherapy may have advantages over postoperative chemotherapy. However, the role of adjuvant RT or preoperative chemotherapy vs. postoperative chemotherapy has not yet been evaluated in randomized clinical trials. Little data are available for use of combined RT and chemotherapy. Decisions about adjuvant or neoadjuvant chemotherapy or RT are left to clinical judgment.⁸⁹⁻⁹¹

Primary treatment depends on the resectability of the sarcoma ([RETSARC-2](#)). Biopsy is performed only if preoperative therapy (category 2B) is considered. CT-guided core biopsy is preferred. Preoperative RT or preoperative chemotherapy (for chemo sensitive histologies) could be considered. Although most patients with retroperitoneal sarcomas (which are often liposarcomas) could be managed with surgical resection with or without intraoperative RT (IORT), the options for other therapy should be discussed, especially if incomplete resection is a reasonable probability. Long-term results of two prospective trials showed favorable 5-year local recurrence-free (60%), disease-free (46%) and OS rates (61%) among patients who had R0 or R1 resection after preoperative RT for intermediate or high grade retroperitoneal sarcoma.⁹² Postoperative RT (category 2B) could be considered in patients with pathologic findings of high grade disease following negative margin resection or for microscopic positive margins (R1 resection). Macroscopic positive margins (R2 resection) should be managed as unresectable disease.

Unresectable retroperitoneal sarcomas are defined as tumors that involve unresectable vital structures or tumors whose removal would

cause unacceptable morbidity. Biopsy is recommended before any treatment for a patient with unresectable or metastatic retroperitoneal sarcoma ([RETSARC-3](#)). Patients with unresectable or metastatic disease have several options for primary treatment after biopsy including chemotherapy or RT to downstage tumors prior to resection.^{64,68} In asymptomatic patients, palliative surgery for symptom control, best supportive care, or observation are additional options. Unresectable tumors that become resectable following primary chemotherapy or RT should be managed as described under resectable disease ([RETSARC-2](#)).

Following primary treatment, if patients have progressive disease or remain unresectable with no downstaging of tumor, management decisions depend on whether patients are symptomatic or asymptomatic. Observation is considered for asymptomatic patients, whereas for symptomatic patients, treatment options are similar to those listed under primary treatment for unresectable or metastases ([RETSARC-3](#)).

Recurrent Disease

For patients with resectable, unresectable or disseminated recurrences, the guidelines recommend the same management after biopsy, as outlined for primary disease ([RETSARC-4](#)). Preoperative RT and/or chemotherapy should be considered for recurrent disease, if not administered previously. Palliative treatment for symptom control (RT, chemotherapy or surgery) and best supportive care are potential options that oncologists should discuss with symptomatic patients. Enrollment in a clinical trial should be considered if an appropriate trial is available.

Surveillance

Patients with low-grade tumors that have been successfully resected should have a follow-up physical examination with imaging

(chest/abdominal/pelvic CT) every 3-6 months for 2-3 years and then annually. Patients with high-grade tumors that have been successfully resected need more frequent surveillance. They should have a follow-up physical examination with imaging (chest/abdominal/pelvic CT) every 3-6 months for 2-3 years, then every 6 months for the next 2 years, and then annually. Chest imaging should be considered in both cases.

Intra-abdominal Soft Tissue Sarcoma

Patients whose lesions are suspected of being gastrointestinal (GI) or intra-abdominal sarcomas should be presented to a multidisciplinary tumor board for evaluation, ideally before primary surgery. Suspicious GI or intra-abdominal lesion(s) are divided into the following groups:

- Gastrointestinal stromal tumors (GIST)
- Intra-abdominal sarcomas other than GIST.

The NCCN guidelines provide separate pathways for GIST and other sarcomas of the intra-abdominal region.

Gastrointestinal Stromal Tumors

GISTs are the most common mesenchymal neoplasms of the gastrointestinal tract, resulting from a mutation in one of the receptor protein tyrosine kinases (KIT, also called CD117).⁹³ Most GISTs (85-95%) are KIT positive. About 5% of GISTs have mutations in the platelet derived growth factor-alpha (PDGFRA) genes and express little or no KIT. Therefore, the diagnosis of GIST for a tumor that is otherwise morphologically typical is not precluded by an absence of KIT staining.⁹⁴ GISTs can arise anywhere along the GI tract but are most common in the stomach (50%) and small bowel (25%).⁹⁵ In patients with a clinically significant GIST(s), symptoms may include early satiety, bloating, GI bleeding, or fatigue related to anemia. Liver metastases and/or dissemination within the abdominal cavity are the most common

clinical manifestations of malignancy. Lymph node metastases are extremely rare. Metastases in the lungs and other extra-abdominal locations are observed only in advanced cases.

Evaluation and Workup

All patients should be managed by a multidisciplinary team with expertise in sarcoma. Essential elements of the workup include the H&P, abdominopelvic CT scan with contrast and/or MRI, chest imaging, endoscopic ultrasound, endoscopy as indicated (if not previously done) and surgical assessment.

Principles of Biopsy

GISTs are soft and fragile, and biopsy may cause tumor hemorrhage and possibly increased risk for tumor dissemination. The decision to obtain a biopsy should be based on the extent of disease and the clinician's degree of suspicion of other malignancies. Endoscopic ultrasound (EUS) biopsy is preferred over percutaneous. Preoperative biopsy may not be appropriate if the tumor is easily resectable. Biopsy is necessary when planning preoperative therapy for suspicious GIST. Optimal pathology of a sufficient amount of tumor tissue is necessary to make the diagnosis of GIST with certainty. Pathology report should include size and mitotic rate of tumor. If available, molecular analysis can be considered. The differential diagnosis of GIST should be considered for any GI sarcoma, as well as for any other intra-abdominal sarcoma. The panel recommends referral to specialized centers for sarcomas with complex or unusual features and expert pathology evaluation of the biopsy or resected mass with the staining of the pathologic specimen for the CD117 antigen (reflecting the KIT receptor tyrosine kinase). Consider using investigational mutational analysis for KIT-negative tumors ([GIST-A](#)).

Targeted Therapy for GIST

GIST tumor had previously been documented to be resistant to conventional chemotherapies. Since KIT activation occurs in the majority of cases of GISTs, in recent years KIT-inhibition has emerged as a promising new treatment for GISTs that are resistant to chemotherapy.

Imatinib mesylate

Imatinib mesylate, a selective inhibitor of the KIT protein tyrosine kinase, has produced durable clinical benefit and objective antitumor responses in most patients with GIST. Multiple clinical trials worldwide have consistently shown the efficacy of imatinib for patients with GIST. Phase II and III studies have demonstrated high overall response rates and exceptionally good progression free survival for patients with unresectable and/or metastatic GIST, as well as showing objective responses in more than 50% of the patients.⁹⁶⁻⁹⁹ In February 2002, FDA approved of imatinib mesylate for the treatment of patients with KIT positive unresectable and/or metastatic malignant GIST.

Two separate phase III trials have assessed the efficacy of imatinib mesylate at two initial dose levels (400 mg daily vs. 800 mg daily, given as 400 mg twice a day) in patients with metastatic or unresectable GIST.^{100, 101} In the Intergroup S0033 trial, at a median follow-up of 4.5 years, there was no statistical differences in PFS (18 months for low dose arm vs. 40 months for higher dose arm) and median OS (55 and 51 months respectively).¹⁰⁰ Following progression on 400 mg daily, 33% of patients that crossed over to the higher dose achieved objective response rates and stable disease. In the EORTC and Australasian trial, increase in progression free survival was observed in patients randomized to higher dose (800 mg/day).¹⁰¹ However, more dose reductions and treatment interruptions were observed in this group of patients.

Available data confirm the safety and efficacy of imatinib at 400 mg/day as the initial standard dose to achieve response induction. Dose escalation to 800 mg/day is a reasonable option for patients progressing on 400 mg/day. Recent data support the use of imatinib at 800 mg/day in patients with exon 9 mutations and advanced GIST. In a randomized EORTC phase III trial, treatment with the high-dose imatinib (800 mg/day) resulted in a significantly superior PFS with a reduction of the relative risk of 61% ($P = 0.0013$), in patients whose tumors expressed an exon 9 KIT.¹⁰²

The clinical outcome after treatment with imatinib depends on the type of mutation found in GIST patients. Patients with exon 11 KIT mutations have longer event-free and OS compared to those with exon 9 KIT mutations or no KIT or PDGFRA mutation. Partial response rate was 83.5% for those with exon 11 mutation compared to 47.8% for those with exon 9 or no kinase mutations.¹⁰³

The most common side effects of imatinib include fluid retention, muscle cramps, nausea, fatigue, abdominal pain and rash. Recent reports have suggested that imatinib is associated with cardiotoxicity. However, analysis of the patients from the large randomized study did not confirm that imatinib induced cardiotoxicity.¹⁰⁴ NCCN GIST Task Force members also suggest that cardiotoxicity is not common with imatinib treatment.¹⁰⁵

Some patients develop primary resistance to imatinib and in others resistance becomes evident after several months, as the disease progresses during treatment with imatinib. Primary resistance is most common in patients with mutations KIT exon 9 and PDGFRA exon 18, whereas secondary resistance develops predominantly in patients who have secondary mutations in KIT exon 11.¹⁰⁶ Imatinib resistance can be managed either by dose escalation or by switching to sunitinib.

Sunitinib malate

Sunitinib malate (previously known as SU11248) is a multi-targeted tyrosine kinase inhibitor that can induce objective responses and control progressive disease in patients with imatinib-resistant GIST.

In a recent randomized phase III placebo-controlled trial, sunitinib produced significant, sustained clinical benefit in patients with imatinib-resistant or imatinib-intolerant GIST.¹⁰⁷ In patients with imatinib-resistant GIST, sunitinib was associated with a significant improvement in median time to progression (27.3 vs. 6.4 weeks) and significantly greater estimated OS. Sunitinib treatment induced partial response in 14 patients (6.8%) and stable disease (22 weeks or more) in 36 patients (17.4%) vs. no partial responses and stable disease in 2 patients (1.9%) on placebo. In the imatinib-intolerant group, 4 out of 9 pts randomized to sunitinib achieved partial response, with progressive disease in only one. In contrast, three of the four patients randomized to placebo had progressive disease at the time of analysis and no partial response was observed. Sunitinib therapy was generally well tolerated. In January 2006, sunitinib malate received FDA approval for the treatment of GIST, after disease progression on or intolerance to imatinib mesylate.

Fatigue, nausea and vomiting were dose-limiting toxicities for sunitinib in clinical trials. Recent reports have shown that sunitinib is also associated with cardiotoxicity and hypothyroidism. In a retrospective analysis of the data from phase I-II trials, 11% of the patients had adverse cardiovascular event including congestive heart failure (CHF) in 8% of patients and absolute reduction in the left ventricular ejection fraction (LVEF) in 28% of patients.¹⁰⁸ Hence, close monitoring for hypertension and LVEF is essential in patients receiving sunitinib, especially in patients with a history of heart disease or cardiac risk factors.

Primary Treatment

Surgery is the primary treatment of choice for localized or potentially resectable GIST lesions. Surgery should produce minimal surgical morbidity. If surgical morbidity would be improved by reducing the size of the tumor, preoperative treatment with imatinib should be considered. GISTs should be handled with care to avoid tumor rupture. The goal is to achieve complete gross resection with an intact pseudocapsule, which is not always possible. GISTs should be handled with care to avoid tumor rupture. If the pseudocapsule is torn, bleeding and tumor rupture may ensue. GISTs often project from the stomach or intestine and tend to displace adjacent structures. Consequently, GISTs can often be lifted away from surrounding organs. After removal of any suspected GIST, postoperative pathology assessment is essential to confirm the diagnosis.

Patients with marginally resectable or resectable GIST lesions with risk of significant morbidity should be treated with imatinib. However, close monitoring is essential, because some patients may rapidly become unresectable. Surgery is recommended if bleeding and/or symptoms are present. PET scans allow rapid assessment of imatinib therapy. Baseline CT with or without MRI followed by subsequent PET scans about 2 to 4 weeks after therapy should be considered to assess therapeutic effect. If there is no progression, resection should be considered, if possible ([GIST-2](#)). In stable and responding patients, imatinib therapy should be continued until maximal response, which may take 3-6 months. If there is progression, as confirmed with CT scan, surgery is recommended after discontinuing imatinib ([GIST-2](#)). Imatinib dosing can be stopped right before surgery and resumed as soon as the patient is able to tolerate oral medications following surgery. Collaboration between the medical oncologist and the surgeon is necessary to determine the appropriateness of surgery following major response or stable disease.

Advanced, unresectable, or metastatic GIST has a very high likelihood of clinical benefit and positive response after treatment with imatinib. Patients with a documented unresectable GIST lesion(s) or patients for whom resection would carry the risk of severe postoperative functional deficit or those with widespread metastatic disease should be treated with imatinib mesylate in the preoperative setting ([GIST-3](#)). Patients should be assessed within 3 months of initiating therapy to determine if their GIST has become resectable. In selected patients, imaging can be done prior to 3 months. CT with or without PET can be used to assess the therapeutic effect. Both CT and PET can identify an abnormal mass and can detect changes in the mass (eg, response or progression).¹⁰⁵ If there is no progression, resection can be considered following surgical consultation. Imatinib therapy should be continued if resection is not feasible. Surgery can be considered if bleeding is present or if there is a limited solitary metastasis.

For patients who experience life threatening side effects with imatinib therapy, that are not managed by supportive treatment, the panel recommends sunitinib therapy prior to surgery, after discontinuing imatinib ([GIST-2](#) and [GIST-3](#)). Few GISTs may be KIT negative, but they may also be sensitive to imatinib. Therefore, it is rational to offer KIT-negative GIST patients a therapeutic trial of imatinib mesylate with close evaluation and follow-up.

Postoperative Treatment

Surgery does not routinely cure GIST. Complete resection is possible in approximately 85% of patients with primary tumors. At least 50% of these patients will develop recurrence or metastasis following complete resection and the 5-year survival rate is about 50%.¹⁰⁹⁻¹¹¹ Median time to recurrence after resection of primary high-risk GIST is about 2 years.

In a single arm, phase II multicenter study (ACOSOG Z9000), adjuvant imatinib prolonged recurrence-free survival following complete

resection and was also associated with improved OS compared to historical controls.¹¹² ACOSOG Z9001 is an intergroup phase III randomized trial of postoperative imatinib (400 mg/day vs. placebo) after resection of primary GISTs. Preliminary results of this trial showed that the use of imatinib as adjuvant therapy following resection of primary GIST improved RFS.¹¹³ Interim analysis included 644 patients from 230 sites with a median follow-up of 1.2 years. Sixty seven percent of patients completed one year of adjuvant imatinib. RFS was 97% in the imatinib arm vs. 83% in the placebo arm, which was statistically different. OS was not different in both arms. Subset analysis showed that RFS was statistically in favor of the imatinib arm (96% for imatinib vs. 67-86% for placebo) in patients with high-risk tumors (greater than 6 cm). However, at this point, the trial results are not conclusive regarding the appropriate duration of treatment, and regarding the effect of imatinib resistance and genetic mutations on the outcome of adjuvant imatinib. Long-term follow-up is ongoing.

Based on these preliminary results, the panel has included adjuvant treatment with imatinib as an alternative to observation, for patients who have undergone complete resection for primary GIST ([GIST-4](#)). Optimum duration of adjuvant treatment has not yet been determined at this time. Adjuvant treatment is recommended for at least 12 months in patients with intermediate to high-risk GIST patients. Higher risk patients may require longer duration of treatment. Postoperative imatinib should be continued if there is persistent gross disease following resection. Additional resection may be considered to remove residual disease. Imatinib treatment should be continued following re-resection regardless of surgical margins until progression. Imatinib treatment should be initiated following incomplete resection, if the patient had not received prior imatinib therapy.

Recurrence of GIST following complete resection should be managed as described for unresectable or metastatic disease ([GIST-3](#)), because

recurrent disease represents locoregional metastatic or infiltrative spread of the malignancy and carries essentially the same prognosis as distant metastases overall.

At this time, continuous use of imatinib is recommended for metastatic GIST until progression ([GIST-4](#)). The patient should be maintained on the same dose and the dose of imatinib should not be increased if patients remain stable without objective progression of the disease. Termination of imatinib therapy in patients with GIST that is refractory to imatinib, has been shown to result in a flare phenomenon,¹¹⁴ which in turn indicates that even in patients with progressive disease on imatinib therapy, there may be a few tumor cells for which imatinib may still be effective. Updated results from a randomized phase III trial by French sarcoma group show that there is significant increase in the rate of progressive disease when imatinib therapy was interrupted in GIST patients with advanced disease.¹¹⁵

Progressive Disease

Progression is defined as appearance of a new lesion or as increase in tumor size. It may be determined using CT or MRI with clinical interpretation; PET may be used if the results are ambiguous ([GIST-5](#)). For limited progressive disease that is potentially easily resectable, surgical resection should be considered.¹¹⁶ Other treatment options include radiofrequency ablation or embolization (category 2B). RT (category 2B) for palliation can be considered in rare patients with bone metastases. Treatment with imatinib should be continued at the same dose or at increased dose as tolerated in patients with limited progressive disease. In patients with widespread systemic disease and good performance status (0-2), imatinib dose should be increased as tolerated. Alternatively, sunitinib can also be considered for both of these indications. In a randomized, multicenter international trial, sunitinib produced significant clinical benefit (disease control and

superior survival) compared with placebo in patients with advanced GIST after failure and discontinuation of imatinib.

Best supportive care should be provided following discontinuation of treatment for patients who are no longer receiving clinical benefit from imatinib or sunitinib. Any patient who has progression of GIST despite prior therapy or who has a recurrence, regardless of presentation, should be considered a candidate for enrollment in a clinical trial, if an appropriate trial is available.

Surveillance

Every patient with localized or potentially resectable GIST should have a thorough H&P every 3 to 6 months; these patients should also have an abdominopelvic CT scan every 3-6 months. An identical schedule is used for patients who have persistent gross residual disease that is unresectable or for completely resected disease ([GIST-4](#)).

Intra-Abdominal Soft Tissue Sarcomas Other Than GIST

Primary Treatment

Definitive surgery with intraoperative RT is the primary therapeutic modality for patients with resectable intra-abdominal GI sarcomas other than GIST or those that occur in the abdomen or pelvis without evidence of metastasis ([GISARC-1](#)). For patients who have resectable primary disease and limited isolated liver metastasis, definitive surgery should be performed for the primary disease. Several options exist for isolated liver lesions, including metastasectomy (with or without preoperative or postoperative chemotherapy with or without RT), radiofrequency ablation or embolization procedures.

Unresectable primary or disseminated metastatic GI sarcomas have a poor prognosis overall ([GISARC-1](#)). Asymptomatic patients can be observed or they can also be treated with chemotherapy, RT, palliative

surgery, best supportive care, and embolization or ablation procedures. If there is response to either chemotherapy or RT, then the tumors should be treated as described above for resectable tumors. Patients can also be enrolled in an appropriate clinical trial.

Surveillance

Every patient, regardless of initial status at presentation or type of primary therapy, should have a thorough H&P with imaging (chest/abdomen/pelvis CT) as clinically indicated. The surveillance schedule varies depending on the type of disease (eg, low versus high grade; resectable versus metastatic) ([GISARC-1](#)).

Recurrent Disease

Regardless of presentation, any patient who has progression of disease despite prior therapy, or who has a recurrence, should be considered a candidate for enrollment in a clinical trial, if an appropriate trial is available. The treatment options depend on the nature and location of the recurrence. If the recurrence is isolated and potentially easily resectable, surgical resection or chemotherapy may be considered; best supportive care is also an option. For unresectable with only a liver recurrence, consider a local ablative procedure (category 2B) such as hepatic resection, radiofrequency ablation, chemoembolization, or other local therapy. Several options are available for patients with disseminated disease as outlined in [GISARC-2](#).

Desmoid Tumors

Desmoid tumors, also known as aggressive fibromatoses, are unique mesenchymal neoplasms, which are often considered “benign malignancies.” Specifically, these tumors are an aggressive fibroblastic proliferation of well-circumscribed, locally invasive, differentiated fibrous tissue. The location and presentation of desmoids vary, from the abdominal wall of young pregnant females, to intra-abdominal mesenteric masses, and to large extremity masses in older men and

women. Abdominal desmoids may be a component of the familial adenomatous polyposis (FAP) syndrome¹¹⁷ and may also arise through elective surgical intervention (eg, colectomy) in susceptible patients.¹¹⁸ In patients who have been treated with prophylactic colectomy, desmoids now represent a more significant cause of morbidity than carcinoma of the colon. Although they do not exhibit the histopathologic features to classify them as sarcomas, desmoid tumors often pose difficult decisions for patients because of the extent of surgery required for optimal control, their high recurrence rate, and their long natural history.¹¹⁹ Desmoid tumors are often categorized as low-grade sarcomas because of their high tendency to recur locally after excision. They can be locally destructive and infiltrative; in one series from Memorial Sloan-Kettering Cancer Center, approximately 10% of patients died of progressive disease.¹²⁰ Although desmoid tumors are often locally invasive, they rarely metastasize. Most patients do not die of their tumors.¹²¹ Desmoids can cause functional morbidity.

Evaluation and Workup

The workup for desmoid tumors includes H&P (with evaluation for Gardner's syndrome), chest imaging, and appropriate imaging of the primary site with CT or MRI as clinically indicated ([DESMSARC-1](#)). All patients should be managed by a multidisciplinary team. Biopsy should be performed for suspicious masses to confirm the diagnosis, and may not be necessary if complete resection is planned. The differential diagnosis for desmoids depends on location; it includes other sarcomas, other malignant carcinomas, and benign lesions. Desmoid tumors of the breast are difficult to differentiate from carcinomas, because desmoids resemble carcinomas clinically and radiologically.¹²²⁻¹²⁴

Primary Treatment

The algorithm has two main branches that depend on whether a patient presents with resectable or unresectable disease ([DESMSARC-1](#)).

Surgery is the primary treatment for resectable desmoid tumors.¹²⁵⁻¹²⁸

Microscopically positive margins may be acceptable if achieving negative margins would produce excessive morbidity. If surgical margins are negative after resection, patients may only be observed. Large tumors can be treated with postoperative RT. For microscopic positive margins, additional resection or high-dose radiation can be considered. RT reduces the risk of recurrence in patients with positive margins and should be considered if a subsequent relapse might lead to increased morbidity.

In the case of unresectable desmoid tumors, amputation should almost never be considered. Functional outcomes are important, and alternatives to amputation may be open to patients who have unresectable desmoid tumors.^{129,130} Desmoids respond slowly to radiation; often 2 years may be required for desmoids to fully respond to radiation. Irradiation of an unresectable desmoid is a reasonable consideration, depending on the possible morbidity of treatment.^{127,131,132} For example, 23 patients received radiation for gross disease, because it was not resectable; 7 sustained local recurrence, yielding a 69% actuarial control rate at 5 years. Kiel and Suit reported even higher control; thus, 8 of 10 patients treated primarily with radiation achieved a complete response without resection (5 patients) or achieved stabilization (3 patients) of their disease after some regression.¹³³

For patients with macroscopic surgical margins, unresectable disease or if surgery would be unacceptably morbid the following options are available: RT, systemic therapy ([SARC-B](#)), radical surgery (if other modalities fail) or observation ([DESMSARC-1](#)). Recurrent disease is managed in the same manner as primary disease

Promising data exist for the use of cytostatic (especially hormonal agents) or cytotoxic systemic therapy.¹³⁴ Cytostatic options include tamoxifen, interferon-alpha and other low-toxicity interventions, such as

sulindac and other nonsteroidal anti-inflammatory agents (including celecoxib), which have been reported to halt progression of these tumors.¹³⁵⁻¹⁴² The risk of cardiovascular events may be increased in patients receiving celecoxib. Physicians prescribing celecoxib should consider this emerging information when weighing the benefits against risks for individual patients (FDA Talk Paper T04-61, Dec 23, 2004). If cytostatic agents fail, cytotoxic therapy with low-toxicity regimens could be considered. Regimens include methotrexate with vinblastine^{143,144} or a doxorubicin-based regimen.¹⁴⁵⁻¹⁴⁸

Imatinib mesylate has also shown some activity against desmoid tumors.^{149,150} Early results from SARC (Sarcoma Alliance for Research through Collaboration) phase II multicenter trial indicate that imatinib has activity in unresectable or difficult-to-resect desmoids tumors.¹⁵¹ This is the largest reported phase II trial of desmoid tumors. The panel has now included imatinib mesylate for the treatment of desmoid tumors.

Surveillance

Postsurgical baseline imaging should be performed after sufficient time has elapsed to allow scarring to be completed after the surgery. Every patient should have an H&P with appropriate imaging every 3-6 months (depending on the risk from the resected disease, anatomic location, etc) for 2-3 years and then annually.

Disclosures for the NCCN Soft Tissue Sarcoma Guideline Panel

At the beginning of each panel meeting to develop NCCN guidelines, panel members disclosed financial support they have received in the form of research support, advisory committee membership, or speakers' bureau participation. Members of the panel indicated that they have received support from the following: Abbott, Adherex, ARIAD, Ascenta, Biomet, Inc., Bristol-Myers Squibb, DePuy Orthopaedics,

Genentech, Genta, Hyatt Corp., Johnson & Johnson, Kanisa, Lilly, National Institutes of Health, Novartis, Ortho Biotech, Pfizer, Robert Urich Foundation, Sanofi-Aventis, Schering Oncology, Smith and Nephew, Southwest Oncology Group, United Health Care, Walther Foundation, Wright Medical Technology and Zimmer.

Some panel members do not accept any support from industry. The panel did not regard any potential conflicts of interest as sufficient reason to disallow participation in panel deliberations by any member.

References

1. Pisters PWT, Casper ES, Mann GN, Weiss M, O'Sullivan B. Soft Tissue Sarcomas. In: Pazdur R, Hoskins WJ, Coia LR, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach. 9th edition, 2005:585-614.
2. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004;54:94-109.
3. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
4. Pisters P. Staging and prognosis. In: Pollock RE, ed. American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Hamilton, Ontario: BC Decker; 2002:80-88.
5. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005;12(1):44-56.
6. Fletcher C, Berman J, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-465.
7. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504-514.
8. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-1926.
9. Greene FL, Page DL, Fleming ID, et al (eds). AJCC Cancer Staging Manual, Sixth Edition, Springer-Verlag: New York 2002.
10. Dileo P, Demetri GD. Update on new diagnostic and therapeutic approaches for sarcomas. Clin Adv Hematol Oncol. 2005;3(10):781-791.
11. Borden EC, Baker LH, Bell RS, et al. Soft Tissue Sarcomas of Adults: State of the Translational Science. Clin Cancer Res.2003;9(6):1941-1956.
12. Clark MA, Fisher C, Judson I, Thomas JM. Soft-Tissue Sarcomas in Adults. N Engl J Med. 2005;353(7):701-711.
13. Lewis JJ, Leung D, Espat J, Woodruff JM, Brennan MF. Effect of reresection in extremity soft tissue sarcoma. Annals of Surgery. 2000;231(5):655-663.
14. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, RS. B. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer. 2003;97(10):2544-2553.
15. National Institute of Health consensus development panel on limb-sparing treatment of adult soft tissue sarcoma and osteosarcomas. Proceedings of Cancer Treatment Symposium,1985:1-5.
16. Ghert MA, Abudu A, Driver N, et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Annals of Surgical Oncology. 2005;12(1):10-17.
17. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Annals of Surgery. 1992;215(3):269-275.
18. DeLaney TF, Trofimov AV, Engelsman M, HD. S. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control. 2005;12(1):27-35.
19. Sadoski C, Suit HD, Rosenberg A, et al. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993;52:223-230.
20. Davis AM, O'Sullivan B, Bell RS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:4472-4477.

21. Alektiar KM, Velasco J, Zelefsky MJ, et al. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. *Int J Radiat Oncol Biol Phys* 2000;48:1051-1058.
22. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. *Ann Surg Oncol* 2002;9:48-56.
23. Tran, QNH, Anne KC, Gottschalk, AR, et al. Clinical Outcomes of Intraoperative Radiation Therapy for Extremity Sarcomas. *Sarcoma* 2006;1-6.
24. Clasby R, Tilling K, Smith MA, et al. Variable management of soft tissue sarcoma: Regional audit with implications for specialist care. *Br J Surg* 1997;84:1692-1696.
25. Heslin MJ, Smith JK. Imaging of soft tissue sarcomas. *Surg Oncol Clin N Am* 1999;8:91-107.
26. Demas BE, Heelan RT, Lane J, et al. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. *AJR Am J Roentgenol* 1988;150:615-620.
27. Hanna SL, Fletcher BD. MR imaging of malignant soft-tissue tumors. *Magn Reson Imaging Clin N Am* 1995;3:629-650.
28. Schwab et al. Skeletal metastases from myxoid liposarcoma; an unusual pattern of distant spread. *Annals of surgical oncology*. 2007;1507-1514.
29. Schwab et al: Spinal metastases from myxoid liposarcoma warrant screening with MRI. *Cancer*. 2007;1815-1822.
30. Tateishi et al. Prognostic significance of MRI findings in patients with Myxoid-round cell liposarcoma. *AJR*. 2004;725-731.
31. Schuetze SM. Utility of positron emission tomography in sarcomas. *Current Opinion in Oncology*. 2006;18(4):369-373.
32. Folpe AL, Lyles RH, Sprouse JT, Conrad EU, III, Eary JF. (F-18) Fluorodeoxyglucose Positron Emission Tomography as a Predictor of Pathologic Grade and Other Prognostic Variables in Bone and Soft Tissue Sarcoma. *Clin Cancer Res*. 2000;6(4):1279-1287.
33. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. *Cancer*. 2005;103(2):339-348.
34. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. *European Journal of Nuclear Medicine*. 2002;29(9):1149-1154.
35. Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. *European Journal of Nuclear Medicine and Molecular Imaging*. 2006;33(11):1290-1295.
36. Geer RJ, Woodruff J, Casper ES, et al. Management of small soft-tissue sarcoma of the extremity in adults. *Arch Surg* 1992;127:1285-1289.
37. Karakousis CP, Emrich LJ, Rao U, et al. Limb salvage in soft tissue sarcomas with selective combination of modalities. *Eur J Surg Oncol* 1991;17:71-80.
38. Pisters PWT, O'Sullivan B, Maki RG. Evidence-Based Recommendations for Local Therapy for Soft Tissue Sarcomas. *J Clin Oncol*. 2007;25(8):1003-1008.
39. Lindberg RD, Martin RG, Romsdahl MM, et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. *Cancer* 1981;47:2391-2397.
40. Yang JC, Chang AE, Baker AR, et al. A randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. *J Clin Oncol* 1998;16:197-203.
41. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. *J Clin Oncol* 1996;14:859-868.

42. Suit HD, Spiro I. Role of radiation in the management of adult patients with sarcoma of soft tissue. *Semin Surg Oncol* 1994;10:347-356.
43. Barkley HT, Martin RG, Romsdahl MM, et al. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. *Int J Rad Oncol Biol Phys* 1988;14:693-699.
44. Wilson AN, Davis A, Bell RS, et al. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. *Eur J Cancer* 1994;30A:746-751.
45. O'Sullivan B, Davis A, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. *J Clin Oncol* (Meeting Abstracts). 2004;22(14_suppl):9007.
46. Kraybill WG, Harris J, Spiro IJ, et al. Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514. *J Clin Oncol*. 2006;24(4):619-625.
47. Pisters PWT, Patel SR, Varma DGK, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: Long-term results from a single institution. *J Clin Oncol* 1997;15:3481-3487.
48. Spiro IJ, Gebhardt MC, Jennings LC, et al. Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. *Semin Oncol* 1997;24:540-546.
49. Rosenberg SA, Tepper JE, Glatstein EJ, et al. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. *Ann Surg* 1982;196:305-315.
50. Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. *Ann Oncol*. 2004;15(11):1667-1672.
51. DeLaney TF SI, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, Rosenberg AL, Rosenthal DI, Miryousefi F, Ancukiewicz M, Harmon DC. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. *Int J Radiat Oncol Biol Phys*. 2003;56(4):1117-1127.
52. Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. *Ann Surg Oncol* 2002;9:535-542.
53. Tierney JF. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. *Lancet* 1997;350:1647-1654.
54. Maki RG. Role of chemotherapy in patients with soft tissue sarcomas. *Expert Review of Anticancer Therapy*. 2004;4(2):229-236.
55. Spira AI, Ettinger DS. The Use of Chemotherapy in Soft-Tissue Sarcomas. *Oncologist*. 2002;7(4):348-359.
56. Bramwell VHC, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 1994;12:1137-1149.
57. Cormier JN, Huang X, Xing Y, et al. Cohort Analysis of Patients With Localized, High-Risk, Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes. *J Clin Oncol*. 2004;22(22):4567-4574.
58. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. *J Clin Oncol* 2001;19:1238-1247.

59. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas. *Oncology*. 2003;65(suppl 2):80-84.
60. Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial. *J Clin Oncol (Meeting Abstracts)*. 2007;25(18_suppl):10008.
61. Alektiar KM, Leung D, Zelefsky MJ, Brennan MF. Adjuvant Radiation for Stage II-B Soft Tissue Sarcoma of the Extremity. *J Clin Oncol*. 2002;20(6):1643-1650.
62. Bramwell VHC, Anderson D, Charette ML and the Sarcoma Disease Site Group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. *Cochrane Database of Systematic Reviews* 2001, Issue 4. Art. No.: CD003293.
63. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. *J Clin Oncol*. 2007;25(21):3144-3150.
64. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. *J Clin Oncol* 1989;7(9): 1208-1216.
65. Antman KH et al. Dana-Farber Cancer Institute studies in advanced sarcoma. *Semin Oncol*. 1990;1(Suppl 2):7-15.
66. Zalupski M, Metch B, Balcerzak S, et al. Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients With Soft-Tissue Sarcomas: A Southwest Oncology Group Study. *J Natl Cancer Inst*. 1991;83(13):926-932.
67. Edmonson J, Ryan L, Blum R, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. *J Clin Oncol*. 1993;11(7):1269-1275.
68. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol* 1993;11(7):1276-1285.
69. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol*. 1995;13(7):1537-1545.
70. Siehl J, Thiel E, Schmittel A, et al. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma. *Cancer*. 2005;104(3):611-617.
71. Siehl JM, Thiel E, Schmittel A, Hutter G, Keilholz U. Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: A two cohort phase II study. *J Clin Oncol (Meeting Abstracts)*. 2006;24(18_suppl):9563.
72. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. *J Clin Oncol* 2002;20:2824-2831.
73. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. *J Clin Oncol*. 2007;25(19):2755-2763.
74. Leu KM, Ostruszka LJ, Schewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. *J Clin Oncol* 2004;22:1706-1712.

75. Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. *International Journal of Cancer*. 2006;119(3):706-711.
76. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients with Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study. *J Clin Oncol*. 2005;23(24):5484-5492.
77. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. *J Clin Oncol*. 2004;22(8):1480-1490.
78. Le Cesne A, Blay JY, Judson I, et al. Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organization for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. *J Clin Oncol*. 2005;23(3):576-584.
79. Issels RD, Lindner LH, Wust P, et al. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised pros. *J Clin Oncol (Meeting Abstracts)*. 2007;25(18_suppl):10009.
80. Grunhagen DJ, Brunstein F, ten Hagen TL, van Geel AN, de Wilt JH, Eggermont AM. TNF-based isolated limb perfusion: a decade of experience with antivasular therapy in the management of locally advanced extremity soft tissue sarcomas. *Cancer Treat Res*. 2004;120:65-79.
81. Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor- α and melphalan for limb-threatening soft tissue sarcoma. *Cancer*. 2006;106(8):1776-1784.
82. Whooley BP, Mooney MM, Gibbs JF, Kraybill WG. Effective follow-up strategies in soft tissue sarcoma. *Seminars in Surgical Oncology*. 1999;17(1):83-87.
83. Whooley BP, Gibbs JF, Mooney MM, McGrath BE, Kraybill WG. Primary extremity sarcoma: what is the appropriate follow-up? *Ann Surg Oncol*. January 1, 2000 2000;7(1):9-14.
84. Kane III JM. Surveillance strategies for patients following surgical resection of soft tissue sarcomas. *Curr Opin Oncol*. 2004;16:328-332.
85. Lewis JJ, Leung DHY, Casper ES, et al. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. *Arch Surg* 1999;134:199-194.
86. Fleming JB, Cantor SB, Varma DG, et al. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. *Cancer* 2001;92:863-868.
87. Singer S, Antman KH, Corson JM, et al. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. *Arch Surg* 1992;127:548-553.
88. Raut C, Pisters PWT. Retroperitoneal sarcomas: Combined-modality treatment approaches. *Journal of Surgical Oncology*. 2006;94(1):81-87.
89. Singer S, Corson JM, Demetri GD, et al. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. *Ann Surg* 1995;221:185-195.
90. Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, Cance WG. Retroperitoneal soft tissue sarcoma. *Cancer*. 2005;104(4):669-675.
91. Windham CT, Pisters PWT. Retroperitoneal Sarcomas. *Cancer Control*. 2005;12(1):36-43.
92. Pawlik TM, Pisters PW, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for

localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. *Ann Surg Oncol*. 2006;13(4):508-517.

93. Sanborn RE, Blanke C. Gastrointestinal stromal tumors and the evolution of targeted therapy. *Clin Adv Hematol Oncol*. 2005;3(8):647-657.

94. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;299:708-710.

95. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. *Am J Surg Pathol* 1999;23:82-87.

96. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;347:472-480.

97. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. *Lancet* 2004;364:1127-1134.

98. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. *Eur J Cancer* 2003;39:2006-2011.

99. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *J Clin Oncol*. 2008;26(4):620-625.

100. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors

expressing the kit receptor tyrosine kinase: S0033. *J Clin Oncol*. 2008;26(4):626-632.

101. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumors crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. *European journal of cancer*. 2005;41:1751-1757.

102. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. *Eur J Cancer*. 2006;42(8):1093-1103.

103. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol*. 2003;21(23):4342-4349.

104. Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. *Eur J Cancer*. 2007;43(6):974-978.

105. Demetri GD, Benjamin R, Blanke CD, et al. NCCN Task Force Report: Optimal Management of Patients with Gastrointestinal Stromal Tumor (GIST)-Update of the NCCN Clinical Practice Guidelines. *JNCCN* 2007;5:S1-S31.

106. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol*. 2006;24(29):4764-4774.

107. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. *Lancet*. 2006;368:1329-1338.

108. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet*. 2007;370(9604):2011-2019.

109. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 2000;231:51-58.
110. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. *Ann Surg Oncol* 2004;11:465-475.
111. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. *Ann Surg*. 2006;244(2):176-184.
112. DeMatteo RP, Owzar K, Antonescu CR, Maki R et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. 2008 Gastrointestinal Cancers Symposium. Abstract 8.
113. DeMatteo R, Owzar K, Maki R, Pisters P et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. 2007 ASCO Annual Meeting. Abstract 10079.
114. Van Den Abbeele AD, Badawi RD, Manola J, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. *J Clin Oncol* (Meeting Abstracts). 2004;22(14_Suppl):3012.
115. Blay J-Y, Le Cesne A, Ray-Coquard I, et al. Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group. *J Clin Oncol*. 2007;25(9):1107-1113.
116. Raut CP, Posner M, Desai J, et al. Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors. *J Clin Oncol*. 2006;24(15):2325-2331.
117. Scott RJ, Froggatt NJ, Trembath RC, et al. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. *Hum Mol Genet* 1996;5:1921-1924.
118. Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. *Gut* 2001;48:515-521.
119. Pignatti G, Barbanti-Brodano G, Ferrari D, et al. Extraabdominal desmoid tumor. A study of 83 cases. *Clin Orthop* 2000;375:207-213.
120. Posner MC, Shiu MH, Newsome JL, et al. The desmoid tumor. Not a benign disease. *Arch Surg* 1989;124:191-196.
121. Sorensen A, Keller J, Nielsen OS, et al. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years. *Acta Orthop Scand* 2002;73:213-219.
122. Godwin Y, McCulloch TA, Sully L. Extra-abdominal desmoid tumor of the breast: review of the primary management and the implications for breast reconstruction. *Br J Plast Surg* 2001;54:268-271.
123. Yamaguchi H, Sakakibara T, Hino M, et al. A case of fibromatosis of the breast. *Breast Cancer* 2002;9:175-178.
124. Kouriefs C, Leris AC, Mokbel K, et al. Infiltrating fibromatosis of the breast: a potential pitfall. *Int J Clin Pract* 2002;56:401-402.
125. Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. *J Clin Oncol*. 2007;25(13):1785-1791.
126. Pritchard DJ, Nascimento AG, Petersen IA, et al. Local control of extra-abdominal desmoid tumors. *J Bone Joint Surg Am* 1996;78:848-854.
127. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. *J Clin Oncol* 1999;17:158-167.

128. Stojadinovic A, Hoos A, Karpoff HM, et al. Soft tissue tumors of the abdominal wall. Analysis of disease patterns and treatment. Arch Surg 2001;136:70-79.
129. Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution. J Clin Oncol 2003;21:1390-1397.
130. Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg 1999;229:866-872.
131. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 1998;42:1007-1014.
132. Schulz-Ertner D, Zierhut D, Mende U, et al. The role of radiation therapy in the management of desmoid tumors. Strahlenther Onkol 2002;178:78-83.
133. Kiel KD, Suit HD. Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors). Cancer 1984;54:2051-2055.
134. Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003;14:181-190.
135. Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors. Cancer 1991;68:1384-1388.
136. Thomas S, Datta-Gupta S, Kapur BM. Treatment of recurrent desmoid tumor with tamoxifen. Aust N Z J Surg 1990;60:919-921.
137. Izes JK, Zinman LN, Larsen CR. Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Urology 1996;47:756-759.
138. Waddell WR, Gerner RE, Reich MP. Nonsteroid anti-inflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol 1983;22:197-211.
139. Lackner H, Urban C, Kerbl R, et al. Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 1997;80:334-340.
140. Chao AS, Lai CH, Hsueh S, et al. Successful treatment of recurrent pelvic desmoid tumor with tamoxifen: case report. Hum Reprod 2000;15:311-313.
141. Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-620.
142. Leithner A, Schnack B, Katterschafka T, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. J Surg Oncol 2000;73:21-25.
143. Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001;92(5):1259-1264.
144. Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer 1989;64:1192-1194.
145. Seiter K, Kemeny N. Successful treatment of a desmoid tumor with doxorubicin. Cancer 1993;71:2242-2244.
146. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993;72:3244-3247.
147. Lynch HT, Fitzgibbons R, Chong S, et al. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 1994;37:260-267.
148. Gega M, Yanagi H, Yoshikawa R, et al. Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Familial Adenomatous Polyposis. J Clin Oncol. 2006;24(1):102-105.
149. Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-2379.

150. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor). J Clin Oncol. 2006;24(7):1195-1203.

151. Chugh R, Maki RG, Thomas DG, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. J Clin Oncol (Meeting Abstracts). 2006;24(18_suppl):9515.